Strategies of Targeting Pathological Stroma for Enhanced Antitumor Therapies
Strategies of Targeting Pathological Stroma for Enhanced Antitumor Therapies
复制标题
针对病理基质增强抗肿瘤治疗的策略
DOI：
10.1016/j.phrs.2019.104401
复制
发表时间：
2019
影响因子：
9.3
通讯作者：
Fuqiang Hu
中科院分区：
文献类型：
--
作者：
Yun Zhu;Fangying Yu;Yanan Tan;Hong Yuan;Fuqiang Hu
癌相关成纤维细胞（CAFs）及其衍生的间质成分构成了促结缔组织肿瘤的特异性病理间质，不仅阻碍了药物/纳米药物在肿瘤中的分布，而且降低了肿瘤细胞对标准治疗的敏感性。因此，病理间质已逐渐成为抗肿瘤治疗的潜在靶点。然而，观察到相反的结果发生在。由于动态基质的异质性和适应性，不同的肿瘤模型采用相同的策略，没有统一的原则，在这种情况下，迫切需要多样化的抗肿瘤治疗策略。在这篇综述中，我们总结了病理间质的起源和特征，并描述了它们对肿瘤治疗反应的重要影响。本文还详细讨论了联合抗肿瘤策略和基质靶向给药系统的设计。总的来说，本综述的主要目的是提高我们对基质在肿瘤进展中的作用的理解，并为靶向病理性基质提供新的见解。
Cancer associated fibroblasts (CAFs) and the derived stromal components constitute specific pathological stroma in desmoplastic tumors, which not only hinder the distribution of drugs/nano-agents in tumors but also reduce the sensibility of tumor cells to standard therapeutics. Consequently, pathological stroma has gradually been termed potential target for antitumor therapy. However, opposite outcomes have been observed to occur with.the same strategy in different tumor models and no general principles have been adopted due to the heterogeneity and adaptivity of dynamic stroma, in which case diversified strategies for antitumor therapies are urgent. In this review, we summarize the origins and characterizations of pathological stroma and describe their critical influence on tumor’s responsiveness to oncotherapy. The design of combinational antitumor strategies and stroma targeting drug delivery systems (DDSs) are also discussed in detail. Collectively, the main purpose of this review is to improve our understanding of the roles of stroma in tumor progression and provide new insights for targeting pathological stroma.